Abstract
In most countries, the supply of corneal material do not meet the demands for corneal transplantation. This has been exacerbated by COVID‐19. Patients have not been seen during lockdown. Many are presenting late. There has been fewer operations done during the pandemic resulting in a backlog. Even in normal times, there are cases of corneal blindness not amenable to cadaveric corneal transplantation. The clinical and research community have two tasks. One is to develop artificial corneae or contructs through biotechnology to replace cadaveric transplantation. The other is to improve keratoprostheses which are used for vascularised corneae and multiple previous failed grafts (Boston KPro1 and similar) and for dry keratinised ocular surface (the OOKP and alternatives).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
